Literature DB >> 30280610

STAT1 and STAT3 mutations: important lessons for clinical immunologists.

Peter Olbrich1,2, Alexandra F Freeman3.   

Abstract

INTRODUCTION: The transcription factors signal transducer and activator of transcription (STAT) 1 and STAT3 fulfill fundamental functions in nonimmune and immune cells. The description and follow-up of patients with germline mutations that result in either loss-of-function or gain-of-function have contributed to our understanding of the pathophysiology of these regulators. Depending on the type of mutations, clinical symptoms are complex and can include infection susceptibility, immune dysregulation as well as characteristic nonimmune features. Areas covered: In this review, we provide an overview about mechanistic concepts, clinical manifestations, diagnostic process, and traditional as well as innovative treatment options aiming to help the clinical immunologist to better understand and manage these complex and rare diseases. Clinical and research papers were identified and summarized through PubMed Internet searches, and expert opinions are provided. Expert commentary: The last several years have seen an explosion in the clinical descriptions and pathogenesis knowledge of the diseases caused by GOF and LOF mutations in STAT1 and STAT3. However, harmonization of laboratory testing and follow-up in international cohorts is needed to increase our knowledge about the natural history of these disorders as well as the development of curative or supportive targeted therapies.

Entities:  

Keywords:  Gain of function (GOF) STAT1; Job’s syndrome; LOF STAT3; chronic mucocutaneous candidiasis; gain of function (GOF) STAT3; hyper IgE syndrome; loss of function (LOF) STAT1

Mesh:

Substances:

Year:  2018        PMID: 30280610     DOI: 10.1080/1744666X.2018.1531704

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  21 in total

Review 1.  Human inborn errors of immunity underlying superficial or invasive candidiasis.

Authors:  Anne Puel
Journal:  Hum Genet       Date:  2020-03-02       Impact factor: 4.132

2.  Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors.

Authors:  Emilie W Borgström; Marie Edvinsson; Lucía P Pérez; Anna C Norlin; Sara L Enoksson; Susanne Hansen; Anders Fasth; Vanda Friman; Olle Kämpe; Robert Månsson; Hernando Y Estupiñán; Qing Wang; Tan Ziyang; Tadepally Lakshmikanth; Carl Inge E Smith; Petter Brodin; Peter Bergman
Journal:  J Clin Immunol       Date:  2022-09-02       Impact factor: 8.542

3.  Anti-Interferon-γ Autoantibodies Impair T-Lymphocyte Responses in Patients with Talaromyces marneffei Infections.

Authors:  Zhao-Ming Chen; Xiao-Yun Yang; Zheng-Tu Li; Wei-Jie Guan; Ye Qiu; Shao-Qiang Li; Yang-Qing Zhan; Zi-Ying Lei; Jing Liu; Jian-Quan Zhang; Zhong-Fang Wang; Feng Ye
Journal:  Infect Drug Resist       Date:  2022-06-28       Impact factor: 4.177

Review 4.  IKAROS Family Zinc Finger 1-Associated Diseases in Primary Immunodeficiency Patients.

Authors:  Cristiane J Nunes-Santos; Hye Sun Kuehn; Sergio D Rosenzweig
Journal:  Immunol Allergy Clin North Am       Date:  2020-08       Impact factor: 3.479

5.  Cryptococcal pneumonia in an adolescent with a gain-of-function variant in signal transduction and activator of transcription 1 (STAT1).

Authors:  Lisa Marinelli; Elizabeth Ristagno; Philip Fischer; Roshini Abraham; Avni Joshi
Journal:  BMJ Case Rep       Date:  2020-04-22

6.  STAT3 gain-of-function mutation in a patient with pulmonary Mycobacterium abscessus infection.

Authors:  Miguel S Gonzalez-Mancera; Britt Johnson; Mehdi Mirsaeidi
Journal:  Respir Med Case Rep       Date:  2020-06-12

7.  Predicting STAT1 as a prognostic marker in patients with solid cancer.

Authors:  Jinguo Zhang; Fanchen Wang; Fangran Liu; Guoxiong Xu
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

8.  Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2.

Authors:  Christopher J A Duncan; Benjamin J Thompson; Rui Chen; Gillian I Rice; Florian Gothe; Dan F Young; Simon C Lovell; Victoria G Shuttleworth; Vicky Brocklebank; Bronte Corner; Andrew J Skelton; Vincent Bondet; Jonathan Coxhead; Darragh Duffy; Cecile Fourrage; John H Livingston; Julija Pavaine; Edmund Cheesman; Stephania Bitetti; Angela Grainger; Meghan Acres; Barbara A Innes; Aneta Mikulasova; Ruyue Sun; Rafiqul Hussain; Ronnie Wright; Robert Wynn; Mohammed Zarhrate; Leo A H Zeef; Katrina Wood; Stephen M Hughes; Claire L Harris; Karin R Engelhardt; Yanick J Crow; Richard E Randall; David Kavanagh; Sophie Hambleton; Tracy A Briggs
Journal:  Sci Immunol       Date:  2019-12-13

9.  A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis-Like Hyperinflammation.

Authors:  Daniel F R Boehmer; Lisa M Koehler; Thomas Magg; Philipp Metzger; Meino Rohlfs; Julia Ahlfeld; Anita Rack-Hoch; Karl Reiter; Michael H Albert; Stefan Endres; Simon Rothenfusser; Christoph Klein; Lars M Koenig; Fabian Hauck
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-27

10.  Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells.

Authors:  Fanchen Wang; Lingyun Zhang; Jiao Liu; Jinguo Zhang; Guoxiong Xu
Journal:  Aging (Albany NY)       Date:  2020-06-09       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.